

INITIATIVE FOR VACCINE RESEARCH
Meningitis Vaccine Project Meeting: A Scientific Workshop
Vaccine Development from Bench to Licensure towards large scale Introduction
A Meningococcal A Conjugate Vaccine for the African Meningitis Belt

Pune, India
10 - 12 February 2010
(25 January, 2010)

WEDNESDAY 10 FEBRUARY 2010

Meningitis epidemics and meningococcal vaccines

9.00 - 9.15	Introduction and Welcome	Marie-Paule Kieny & Cyrus Poonawalla
9.15 - 9.30	A tribute to Dr. Charles Mérieux	Alain Mérieux (by Videocon)
9.30 - 10.00	The scope of the epidemic meningitis in Africa (political, public health and economic issues)	Francis Nkrumah
10.00 - 10.45	Meningitis epidemics in Africa: historic overview, current trends	Brian Greenwood William Perea
10.45 - 11.00	Meningococcal meningitis in India	David Sinclair
<i>11.00 - 11.30</i>	<i>Coffee/tea break</i>	
11.30 - 11.55	The origins of MVP	Teresa Aguado, Luis Jodar
11.55 - 12.20	<i>MenAfriVac</i> as an example of a successful “push” business strategy to develop a needed vaccine	Marc LaForce
12.20 - 13.00	Discussions on morning presentations	Teresa Aguado, moderator

13.00 - 14.00 Lunch

Pharmaceutical Development

14.00 - 14.20	Evolution of conjugation techniques	Carl Frasch
14.20 - 14.40	Men A conjugation technology	Robert Lee
14.40 - 15.00	Challenges in scaling up Men A conjugation and purification technology	Suresh Beri, Jayant Joshi
15.00 - 15.20	Fermentation technology	Hitesh Malviya
15.20 - 15.40	Lyophilization and spray-drying stabilization studies	Akshay Goel, Jean-Marie Préaud
15.40 - 16.00	Lessons learned in technology transfer	Jean-Marie Préaud
<i>16.00 - 16.30</i>	<i>Coffee/tea break</i>	
16.30 - 18.00	Tour of Serum Institute manufacturing facilities	SIIL

THURSDAY 11 FEBRUARY 2009

Pharmaceutical Development cont'd

09.00 - 09.20	Results of vaccine stability studies	K. Suresh
09.20 - 09.40	Characterization of <i>MenAfrivac</i>	Ian Feavers
09.40 - 10.00	Lessons learned from the MVP/SIIL partnership	Suresh Jadhav
10.00 - 10.30	Discussion on pharmaceutical development	Subhash Kapre, moderator

10.30 - 11.00 Coffee/tea break

Clinical Development

11.00 - 11.15	Introduction and historical overview	Simonetta Viviani
11.15 - 11.30	Rationale and clinical plan to evaluate <i>MenAfriVac</i>	Marie-Pierre Preziosi
11.30 - 11.50	Choice of assays	Musa Hassan-King
11.50 - 12.40	Correlates of protection, assay development and validation	Ray Borrow, Cheryl Elie, Margaret Bash
12.40 - 13.00	Discussion	Musa Hassan-King, moderator

13.00 - 14.00 Lunch

14.00 - 15.15	Results of clinical studies	Urmila Thatte, Samba Sow, Adebayo Akinsola, Aldiouma Diallo, Siddhivinayak Hirve, Abraham Hodgson, Milagritos Tapia
15.15 - 16.00	Statistical methods	Yuxiao Tang, Brian Plikaytis, Varsha Parulekar

16.00 - 16.30 Coffee/tea break

16.30 - 17.00	Capacity building at clinical trial sites	Lionel Martellet, Jacques Hervé, Véronique Mazarin- Diop, Manisha Ginde
17.00 - 17.20	Tetanus control and <i>MenAfriVac</i> : a potentially important additional public health benefit	Marc LaForce
17.20 - 18.00	Discussion and future plans	Prasad Kulkarni, moderator

FRIDAY 12 FEBRUARY 2009

Regulatory issues, vaccine introduction and impact assessment

9.00 - 9.50	The fight against epidemic meningitis in the African health agenda context	Déo Nshimirimana
9:50 - 10.10	The <i>MenAfriVac</i> regulatory strategy	Graciela Spizzamiglio, Milind Javadekar, Muriel Socquet
10.10 - 10.30	Manufacturing capacity and harmonizing supply and demand	Subash Kapre, Carol Tevi-Benissan
10.30 - 11.00	Vaccine introduction and resource mobilization	Mamoudou Djingarey, Carol Tevi-Benissan
11.00 - 11.30	<i>Coffee/tea break</i>	
11.30 - 11.55	Pharmacovigilance	Katharina Hartmann
11:55 - 12.20	Impact assessment: surveillance and vaccine effectiveness studies	Mamoudou Djingarey, Nancy Messonnier
12.20 - 12.40	Impact assessment: carriage studies and the MenAfriCar consortium	Dominique Caugant, Brian Greenwood
12.40 - 13.00	Communication strategy	Monique Berlier
13.00 - 13.30	Discussion and lessons learned (regulatory, introduction and communication)	Francis Nkrumah, moderator
13.30 - 14.00	Final remarks and closure	Marc LaForce & Cyrus Poonawalla

Meeting Rapporteur: Valentina Picot
Responsible Officer: Marie-Pierre Préziosi
Administrative Officer: Maggie Ndowa

The workshop is co organized by Fondation Mérieux, PATH
and the World Health Organization.



Special thanks is given to Serum Institute of India Ltd. for their collaboration in organizing
& hosting the meeting and to USAID & the Norwegian Research Council
for providing their generous financial support.